Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder

Summary

The goal of this clinical trial is to study the NiNA System and how it works to treat overactive bladder. Up to 290 participants will be enrolled in the study in the USA and Australia.

The investigational NiNA System includes a wearable neurostimulator device ("NiNA" or "Device"), a flexible wrap to secure the Device to the calf during treatment of the saphenous nerve (SAFN), with smartphone-based control application with patient support features that allow users to control the stimulation therapy and receive reminder on days they are supposed to provide therapy ("NiNA App") or an enhanced smartphone-based control application which also has patient support features and educational multi-media content ("NiNA Care App").

The main questions the study aims to answer are: 1) How does the NiNA system compare to a common overactive bladder (OAB) medication; 2) How well does the NiNA system improve overactive bladder symptoms; and, 3) Does the NiNA system produce any unwanted side-effects.

In the study half the participants randomly receive the NiNA system and the other half first receive the OAB medication and later are treated with the NiNA System.

The Participants in the investigative Device arm (NiNA) will:

Provide NiNA system treatments very day for 30 minutes during a 28 day induction/restore period. This is followed by maintenance treatments (30 minutes, 3-times a week) until 12 weeks, when the primary endpoint data are measured. Participants continue maintenance (30 minutes, 3-times a week) for the remaining 52 weeks of the study.

Participants in the OAB medication arm will:

Take a capsule every day (tolterodine tartrate extended release (ER) 4 mg) for twelve weeks.

At 12 weeks, OAB medication arm Participants will stop taking the OAB medication and cross-over to treatment with the NiNA system. One-third of the cross-over Participants will be use a phone-based software application that allows them to control the neurostimulator and receive reminders on days the are scheduled to provide their therapy (NiNA App) and the other two-thirds of the cross-over Participants will use a phone based software application that also contains educational videos that reinforce the therapy (NiNA Care App). Assignment to each arm is random.

The study will measure primary and secondary endpoints completely remotely using digital questionnaires that are presented to Participants on a specialized software application installed on their phones ("Study App"):

Changes in OAB symptoms at a defined set of time points using the following instruments:

1. Bladder diary (3-day, consecutive);
2. Self-administered and validated Quality-of-Life questionnaires (see Effectiveness Assessments);
3. Additional assessments of participant satisfaction and preferences will be obtained using participant study surveys and questionnaires at defined study time points.

Conditions

• Overactive Bladder (OAB)

Interventions

DEVICE

Wearable neurostimulation system for saphenous nerve stimulation

Device: NiNA System The NiNA System includes a wearable neurostimulator device and stimulation matrix with 6 conductive pads that provide transcutaneous stimulation ("NiNA"), that are secured to the upper calf during treatment using a flexible wrap. The system includes a either a) a basic version smartphone-based control application with patient support features ("NiNA with NiNA App") or a more advanced version which also includes multi-media educational content ("NiNA with NiNA Care App"). The system uses field steering controls to improve targeted electrical stimulation of the saphenous nerve.

DRUG

tolterodine tartrate 4 mg extended release

once daily tolterodine tartrate 4mg ER

Sponsors & Collaborators

• NinaMED Pty Ltd

  lead INDUSTRY

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-09-10

Primary Completion

2027-12-10

Completion

2028-01-30

FDA Drug

Yes

FDA Device

Yes

Countries

• United States
• Australia

Study Locations